ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.295,98
-0,59%
S&P 500
6.021,63
0,57%
Dow Jones
44.860,31
0,28%
Euro vs US Dollar
1,04826
-0,08%
Bitcoin
92.710,89
0,80%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Acrivon Therapeutics Inc (ACRV)

  7. Acrivon Therapeutics Inc (ACRV) News

ACRV

Acrivon Therapeutics (ACRV)

Acrivon Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ACRV
DatumZeitQuelleÜberschriftSymbolFirma
25/11/202422h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
18/11/202422h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
18/11/202422h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
18/11/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
18/11/202422h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
18/11/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
18/11/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
13/11/202413h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRVAcrivon Therapeutics Inc
13/11/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
13/11/202413h00GlobeNewswire Inc.Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
21/10/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
17/10/202414h00GlobeNewswire Inc.Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR SymposiumNASDAQ:ACRVAcrivon Therapeutics Inc
16/10/202422h00GlobeNewswire Inc.Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACRVAcrivon Therapeutics Inc
11/10/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
11/10/202414h00GlobeNewswire Inc.Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent ActivityNASDAQ:ACRVAcrivon Therapeutics Inc
04/10/202400h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/09/202412h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
14/09/202409h10GlobeNewswire Inc.Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data AnalysisNASDAQ:ACRVAcrivon Therapeutics Inc
10/09/202414h00GlobeNewswire Inc.Acrivon Therapeutics to Present at the Cantor Global Healthcare ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
09/09/202413h00GlobeNewswire Inc.Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
23/08/202422h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202422h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202422h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202422h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202422h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202422h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202422h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
16/08/202422h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
13/08/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
13/08/202414h00GlobeNewswire Inc.Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACRV

Kürzlich von Ihnen besucht

TG
NOV
Novo Nordisk
USOTC
ADDYY
Adidas (QX)
NASDAQ
AMZN
Amazon.com
TG
CBK
Commerzbank
NYSE
MRK
Merck
TG
ALV
Allianz
DBI
TDXP
Tec DAX
AMEX
SPY
SPDR S&P 500
USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
XLE
Energy Select Sector SPDR
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
NASDAQ
GOOGL
Alphabet
CCOM
US100
US Tech 100
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten

BLACK FRIDAY

ADVFN

Seit 25 Jahren im Geschäft 1999-2024

Sparen Sie bis zu 60%* für Euronext Level 2

1 Jahr 40%, 2 Jahre 50% und *3 Jahre 60%

*Über 3 Jahre 1094.04€, jetzt nur noch 437.62€